Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
Arrhythmias are clinically prevalent with a high mortality rate. They impose a huge economic burden, thereby substantially affecting the quality of life. Sodium-glucose co-transporter 2 inhibitor (SGLT2i) is a new type of hypoglycemic drug, which can regulate blood glucose level safely and effective...
Main Authors: | Yuling Jing, Ruixue Yang, Wen Chen, Qiang Ye |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.898718/full |
Similar Items
-
Benefits of SGLT2 inhibitors in arrhythmias
by: Jinghan Gao, et al.
Published: (2022-10-01) -
Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study
by: Sergio Gamaza-Chulián, et al.
Published: (2021-09-01) -
Sizing SGLT2 Inhibitors Up: From a Molecular to a Morpho-Functional Point of View
by: Silvia Prosperi, et al.
Published: (2023-09-01) -
Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats
by: Peng Zhong, et al.
Published: (2023-11-01) -
Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin
by: Shih-Jie Jhuo, et al.
Published: (2021-06-01)